[Boost and hypofractionation in DCIS].
作者信息
Dunst Jürgen, Krug David
机构信息
Klinik für Strahlentherapie Kiel, UKSH, Kiel, Deutschland.
出版信息
Strahlenther Onkol. 2022 Dec;198(12):1122-1124. doi: 10.1007/s00066-022-02016-y. Epub 2022 Oct 20.
Abstract
摘要
相似文献
1
[Boost and hypofractionation in DCIS].[导管原位癌中的强化与大分割放疗]
Strahlenther Onkol. 2022 Dec;198(12):1122-1124. doi: 10.1007/s00066-022-02016-y. Epub 2022 Oct 20.
2
[Quality of life in DCIS patients after breast-conserving surgery plus adjuvant radiotherapy: conventional fractionated vs. hypofractionated radiotherapy, with and without boost].
Strahlenther Onkol. 2021 Jun;197(6):565-566. doi: 10.1007/s00066-021-01764-7. Epub 2021 Mar 24.
3
Radiation therapy after breast conserving surgery increases long-term breast conservation for DCIS patients.保乳手术后进行放射治疗可提高导管原位癌（DCIS）患者的长期保乳率。
Breast. 2018 Feb;37:179-180. doi: 10.1016/j.breast.2017.10.013.
4
[Small DCIS: In favour of postoperative radiotherapy].[微小导管原位癌：支持术后放疗]
Gynecol Obstet Fertil. 2012 Jun;40(6):384-6. doi: 10.1016/j.gyobfe.2012.04.002. Epub 2012 May 31.
5
The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: a meta-analysis of observational studies.在导管原位癌患者中，大分割放疗和超分割放疗作为辅助放疗的作用：一项观察性研究的荟萃分析。
Radiother Oncol. 2015 Jan;114(1):50-5. doi: 10.1016/j.radonc.2015.01.001. Epub 2015 Jan 14.
6
Should all patients undergoing breast conserving therapy for DCIS receive radiation therapy? Yes. Radiation therapy, an important component of breast conserving treatment for patients with ductal carcinoma in situ of the breast.所有接受保乳治疗的导管原位癌患者都应该接受放射治疗吗？是的。放射治疗是乳腺导管原位癌患者保乳治疗的重要组成部分。
J Surg Oncol. 2007 Jun 15;95(8):610-3. doi: 10.1002/jso.20711.
7
Comparing hypofractionated and conventionally fractionated whole breast irradiation for patients with ductal carcinoma in situ after breast conservation: a propensity score-matched analysis from a national multicenter cohort (COBCG-02 study).保乳术后导管原位癌患者的大分割与常规分割全乳照射比较：一项来自全国多中心队列的倾向评分匹配分析（COBCG - 02研究）
J Cancer Res Clin Oncol. 2021 Jul;147(7):2069-2077. doi: 10.1007/s00432-020-03483-5. Epub 2021 Jan 2.
8
Hypofractionation and concomitant boost to deliver adjuvant whole-breast radiation in ductal carcinoma in situ (DCIS): a subgroup analysis of a prospective case series.低分割同期加量推量照射在导管原位癌（DCIS）中的辅助全乳放疗：一项前瞻性病例系列研究的亚组分析。
Med Oncol. 2014 Feb;31(2):838. doi: 10.1007/s12032-014-0838-2. Epub 2014 Jan 12.
9
Adoption of hypofractionated radiation therapy for breast cancer after publication of randomized trials.随机试验发表后，乳腺癌采用分割放射治疗。
Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1001-9. doi: 10.1016/j.ijrobp.2014.09.032.
10
Adjuvant radiotherapy for DCIS.导管原位癌的辅助放疗
Lancet. 2000 Jun 10;355(9220):2071-2; author reply 2072-3. doi: 10.1016/S0140-6736(05)73522-4.
本文引用的文献
1
Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.在非低危型乳腺导管原位癌（BIG 3-07/TROG 07.01）中，放射剂量和分割方案：一项随机、析因、多中心、开放标签、III 期研究。
Lancet. 2022 Aug 6;400(10350):431-440. doi: 10.1016/S0140-6736(22)01246-6.
2
Breast radiotherapy for ductal carcinoma in situ: could less be more?
Lancet. 2022 Aug 6;400(10350):408-410. doi: 10.1016/S0140-6736(22)01381-2.
3
Moderately hypofractionated post-operative radiation therapy for breast cancer: Systematic review and meta-analysis of randomized clinical trials.中等分割术后放疗治疗乳腺癌：随机临床试验的系统评价和荟萃分析。
Breast. 2022 Apr;62:84-92. doi: 10.1016/j.breast.2022.01.018. Epub 2022 Feb 3.
4
Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.随机 III 期临床试验评估手术切除后低危导管原位癌的放疗：NRG 肿瘤学/RTOG9804 的长期报告。
J Clin Oncol. 2021 Nov 10;39(32):3574-3582. doi: 10.1200/JCO.21.01083. Epub 2021 Aug 18.
5
Association of Radiotherapy Boost for Ductal Carcinoma In Situ With Local Control After Whole-Breast Radiotherapy.放疗对导管原位癌的影响与全乳放疗后局部控制的关系。
JAMA Oncol. 2017 Aug 1;3(8):1060-1068. doi: 10.1001/jamaoncol.2016.6948.
6
RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.放射治疗肿瘤学组（RTOG）9804：一项针对低风险导管原位癌的前瞻性随机试验，比较放疗与观察的效果。
J Clin Oncol. 2015 Mar 1;33(7):709-15. doi: 10.1200/JCO.2014.57.9029. Epub 2015 Jan 20.
7
The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: a meta-analysis of observational studies.在导管原位癌患者中，大分割放疗和超分割放疗作为辅助放疗的作用：一项观察性研究的荟萃分析。
Radiother Oncol. 2015 Jan;114(1):50-5. doi: 10.1016/j.radonc.2015.01.001. Epub 2015 Jan 14.
8
Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.保乳手术后早期乳腺癌患者行全乳放疗或加量放疗：一项随机 3 期临床试验 20 年随访结果
Lancet Oncol. 2015 Jan;16(1):47-56. doi: 10.1016/S1470-2045(14)71156-8. Epub 2014 Dec 9.
9
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.乳腺导管原位癌放射治疗随机试验综述
J Natl Cancer Inst Monogr. 2010;2010(41):162-77. doi: 10.1093/jncimonographs/lgq039.
10
The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.欧洲癌症研究与治疗组织（EORTC）“加量放疗与不加量放疗”试验中保乳治疗加量对美容效果的影响。EORTC放疗与乳腺癌协作组。欧洲癌症研究与治疗组织。
Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):677-85. doi: 10.1016/s0360-3016(99)00211-4.
Zotero 插件